IAVI Report

Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of the company’s Phase III Mosaico trial.

Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.

A slew of potential advances in treating and preventing tuberculosis offers new hope in the battle against one of the oldest human afflictions.

Regulatory approval of a vesicular stomatitis virus-based vaccine paves the way for use of this viral vector in other vaccines.

Africa is contributing far more than samples to scientific research. The continent’s scientists are actively engaged in developing and testing novel HIV vaccine candidates.

A conversation with Anatoli Kamali and Penny Moore about the rise of HIV vaccine science in Africa

This year’s flu season was one for the books, and it swung the spotlight directly on vaccines. The predominant strain of influenza virus that circulated in the US, an influenza A subtype known as H3N2, was particularly virulent, leaving thousands dead and sending many more to the hospital. And the seasonal flu vaccine was only…

If you are a regular IAVI Report reader, it will come as no surprise that antibodies, particularly those that are both potent and able to neutralize a broad swath of global HIV isolates, are all the rage. Such antibodies have been isolated in droves from HIV-infected people and are now fueling vaccine design efforts. They are also being…

 In 2007, I was in Cape Town to attend a symposium on the challenges of global vaccine development. At that meeting, and during my visits to nearby clinical research centers, the mood was somber. Just weeks before, two HIV vaccine efficacy trials, known as STEP and Phambili, had ground to a halt. These trials were testing…

“It was the best of times, it was the worst of times…” So begins Charles Dickens’s famous historical novel A Tale of Two Cities, published in 1859. Dickens was describing the years leading up to the French Revolution, yet it is an oddly apt description of the current state of the vaccine field.” This October,…

There is more optimism than ever that researchers are on the path to developing vaccines and antibodies that can help stem HIV’s persistent spread.

After decades of work, scientists are now advancing rationally designed vaccine candidates meant to induce a long sought-after broadly neutralizing antibody response.